Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation

Jun Tang,1,2 Mark E. Lobatto,1,3 Laurien Hassing,1,3 Susanne van der Staay,1,3 Sarian M. van Rijs,1,3 Claudia Calcagno,1 Mounia S. Braza,1 Samantha Baxter,1 Francois Fay,1 Brenda L. Sanchez-Gaytan,1 Raphaël Duivenvoorden,3 Hendrik B. Sager,4 Yaritzy M. Astudillo,5 Wei Leong,1,2 Sarayu Ramachandran,1 Gert Storm,6,7 Carlos Pérez-Medina,1 Thomas Reiner,8 David P. Cormode,9 Gustav J. Strijkers,10 Erik S. G. Stroes,3 Filip K. Swirski,4 Matthias Nahrendorf,4 Edward A. Fisher,5 Zahi A. Fayad,1 Willem J. Mulder1,3*

Inflammation drives atherosclerotic plaque progression and rupture, and is a compelling therapeutic target. Consequently, attenuating inflammation by reducing local macrophage accumulation is an appealing approach. This can potentially be accomplished by either blocking blood monocyte recruitment to the plaque or increasing macrophage apoptosis and emigration. Because macrophage proliferation was recently shown to dominate macrophage accumulation in advanced plaques, locally inhibiting macrophage proliferation may reduce plaque inflammation and produce long-term therapeutic benefits. To test this hypothesis, we used nanoparticle-based delivery of simvastatin to inhibit plaque macrophage proliferation in apolipoprotein E−/− mice (Apoe−/−) with advanced atherosclerotic plaques. This resulted in the rapid reduction of plaque inflammation and favorable phenotype remodeling. We then combined this short-term nanoparticle intervention with an 8-week oral statin treatment, and this regimen rapidly reduced and continuously suppressed plaque inflammation. Our results demonstrate that pharmacologically inhibiting local macrophage proliferation can effectively treat inflammation in atherosclerosis.

INTRODUCTION

Atherosclerosis, primarily affecting large and midsized arteries, is a lipid-driven inflammatory disease and the underlying cause of most cardiovascular events (1). Macrophage accumulation plays a major role in atherosclerotic plaque progression, promotes maladaptive inflammation, and aggravates the disease (2, 3). Therefore, effective therapeutic strategies to reduce plaque macrophage accumulation are a promising approach to dampening inflammation and treating the disease.

Local macrophage accumulation has long been believed to primarily associate with the recruitment rate of blood Ly-6C<sup>high</sup> monocytes, as well as apoptosis and possibly emigration of plaque macrophages (4, 5). Therefore, anti-inflammatory therapeutic strategies currently being developed focus on blocking monocyte recruitment (6, 7), promoting macrophage apoptosis (8, 9), or increasing macrophage emigration (10). The established macrophage accumulation paradigm is now being revisited. Recent studies demonstrated that local macrophage proliferation can maintain macrophage accumulation in inflammatory (11) and normal tissues (12, 13). In the context of atherosclerosis, macrophage proliferation dominates in advanced atherosclerotic plaques, in which proliferation contributed more than 80% of local macrophage accumulation over a 1-month period (14). However, whether directly inhibiting macrophage proliferation can reduce plaque inflammation and produce therapeutic benefits for atherosclerosis remains unknown.

3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, also known as statins, specifically act on the mevalonate pathway, which is indispensable for cell membrane attachment of many small guanosine triphosphatases (GTPases) and their function in promoting cell proliferation (15, 16). In cell culture, statins effectively inhibit the proliferation of breast cancer cells (17, 18), smooth muscle cells (19), and macrophages (20). We incorporated the HMG-CoA reductase inhibitor simvastatin in a high-density lipoprotein nanoparticle (S-HDL) and achieved specific delivery to plaque macrophages (21). Here, we show that S-HDL inhibits macrophage proliferation in advanced atherosclerotic plaques, reduces plaque inflammation, and, when combined with oral statin treatment, generates long-term therapeutic benefits.

RESULTS

Study focuses on S-HDL’s therapeutic mechanism and efficacy

Our study focused on inhibiting macrophage proliferation to treat plaque inflammation in apolipoprotein E−/− mice (Apoe−/−) with advanced atherosclerosis. Using a combination of flow cytometry, magnetic resonance imaging (MRI), near-infrared fluorescence (NIRF) imaging, laser capture microdissection, and mRNA profiling, we dissected the mechanism by which S-HDL exerts its anti-inflammatory effect (Fig. 1A).

Having acquired a mechanistic understanding of S-HDL, we designed a two-step treatment regimen that consisted of a 1-week intravenous S-HDL treatment followed by an 8-week oral statin routine intervention (Fig. 1B). After nine weeks of treatment, we used immunostaining, laser...
capture microdissection, mRNA profiling, blood chemistry, and histology to study the regimen’s effects on advanced plaque inflammation and phenotype in ApoE−/− mice (Fig. 1B).

**S-HDL does not affect Ly-6Chigh monocyte recruitment**

S-HDL was labeled with 86Zr (fig. S1A), and its biodistribution was evaluated in wild-type B6 and ApoE−/− mice (fig. S1B). We observed a more than fourfold higher S-HDL aortic arch accumulation in atherosclerotic ApoE−/− mice compared to healthy B6 mice (fig. S1C). Clearance occurs primarily through mononuclear phagocyte system organs (fig. S1, D and E), with a favorable aorta-to-liver accumulation ratio in diseased mice (fig. S1F). Blocking Ly-6Chigh monocyte recruitment reduces atherosclerotic plaque inflammation (7), whereas acute and chronic psychosocial stress aggravates vascular inflammation due to monocytosis (22, 23). To investigate S-HDL’s effects on monocyte recruitment to the plaque, we first characterized Ly-6Chigh monocyte targeting dynamics after a single S-HDL intravenous injection to ApoE−/− mice with advanced atherosclerosis. In plasma and in association with Ly-6Chigh monocytes, S-HDL had about a 20-hour blood half-life, without affecting important recruitment proteins CCR2 and CD115 (fig. S2). A 1-week nanotherapy treatment course consisting of four intravenous S-HDL injections at a simvastatin dose of 60 mg/kg, which corresponds to a simvastatin dose of 5 mg/kg in humans (24), did not affect the blood Ly-6Chigh monocyte levels (Fig. 2, A and B). The aortas showed no change in total mRNA levels of the key genes involved leukocyte recruitment (Ccl2, Icam1, Vcam1, Ccl3, Ccl5, and Cxcl12) and macrophage inflammation state (Tnfa, Il1a, Il1b, and Spp1) after treatment (Fig. 2C). Flow cytometry revealed similar expression patterns of ICAM-1 and VCAM-1 (Fig. 2D), two critical adhesion molecules involved in monocyte recruitment. Finally, using flow cytometry, we quantified Ly-6Chigh monocytes in the whole aortas and found no difference between placebo and S-HDL–treated animals (Fig. 2, E and F). In line with previous studies (14, 23), little Ly-6Clow monocytes were observed in plaques (Fig. 2E).

S-HDL reduces local macrophage accumulation in plaques

We previously found that S-HDL reduced macrophage levels in ApoE−/− mice that received an HCD for 26 weeks (21). Here, we used an iHCD that induces established plaques within 12 weeks (14) and advanced plaques in aortic roots after 16 to 20 weeks.

We developed a delayed-enhancement T1-weighted MRI (DE-MRI) protocol to evaluate changes in atherosclerotic plaque phenotypes (25, 26). Similar to DE-MRI after myocardial infarction (MI) (27), in aortic roots, this technique also reports on inflammation. Figure S3 outlines the procedure that was used to locate and measure signal enhancement in ApoE−/− mouse aortic roots and arches after intravenously administered Gd-DTPA (gadolinium–diethylenetriamine pentacetic acid). We measured signal enhancement before and after one week of S-HDL treatment. We found that, in contrast with placebo-treated mice, a 1-week S-HDL treatment regimen decreased signal enhancement in aortic roots, which indicates a plaque phenotype change (Fig. 3, A and B). These in vivo MRI data were corroborated by NIRF imaging that showed decreased dye-labeled albumin accumulation in the same tissues (Fig. 3, C and D).

Immunofluorescence staining revealed that S-HDL reduced macrophage accumulation in aortic roots by 45% (P < 0.01) in ApoE−/− mice receiving iHCD. Using laser capture microdissection, we isolated plaque macrophages and measured the expression of key inflammatory genes Tnfa, Ccl2, Icam1, Vcam1, Ccl3, Ccl5, and Cxcl12. This process revealed significantly reduced Tnfa, Ccl2, Vcam1, and Ccl3 expression in mice treated with S-HDL (Fig. 3G). In line with the reduced macrophage burden, using a bead-based protocol (28), we observed lower numbers of emigrating macrophages (fig. S4) but no changes in macrophage apoptosis (fig. S5).

**S-HDL inhibits plaque macrophage proliferation**

The above data demonstrate that S-HDL treatment significantly decreased macrophage accumulation but did not affect Ly-6Chigh monocyte recruitment, macrophage emigration, or macrophage apoptosis. Recent research shows that cell proliferation is the primary contributor to macrophage accumulation in advanced atherosclerotic plaques (14). In light of this discovery, we evaluated S-HDL’s ability to reduce macrophage proliferation. Twenty-four hours before the study end point, we injected 5-bromo-2′-deoxyuridine (BrdU) into the peritoneal cavity of mice that had received 1 week of S-HDL treatment (four intravenous injections; simvastatin, 60 mg/kg). BrdU’s short systemic half-life renders this a pulse-chase experiment that labels actively proliferating cells for only a short period of time. We isolated aortic macrophages and monocytes for analysis by flow cytometry (Fig. 4, A to C). We found 25% fewer BrdU+ macrophages in the aortas of mice treated with S-HDL than the placebo group. In accordance with previous work (14), we did not observe robust monocyte proliferation (Fig. 4C). To have a complete view on plaque macrophage proliferation, we subsequently focused on aortic...
Tang et al. Sci. Adv. 2015;1:e1400223 3 April 2015
3 of 9

RESEARCH ARTICLE

Fig. 2. S-HDL does not affect Ly-6C<sup>+</sup> monocyte recruitment to atherosclerotic plaques. (A and B) Apoe<sup>−/−</sup> mice receiving a 20-week iHCD were treated with either 1-week S-HDL intravenous injection (n = 9) or placebo (phosphate-buffered saline (PBS), n = 9). (A) Representative graph. (B) Quantification. (C) Tested gene expression was normalized to housekeeping gene Hprt1. Statistics were calculated using Student's t test between S-HDL (n = 7) and placebo (n = 7). (D) Endothelial cells (ECs) were separated from aortas, and the cells’ ICAM-1 and VCAM-1 levels were measured by flow cytometry. Gray-filled graphs in (D) are isotype controls. (E and F) Cells from 18 aortas (n = 9 for S-HDL and n = 9 for placebo) were released by enzyme digestion, and they were identified and numerated by flow cytometry. Lineage (Lin) included antibodies recognizing CD90, B220, CD49b, NK1.1, Ly-6G, and Ter-119. Quantification is shown in (F). All graphs are presented as means ± SEM. Differences between placebo and S-HDL were calculated by Mann-Whitney U tests if not particularly noted, and none of the comparisons showed significant differences.

roots, in which atherosclerosis development is the most advanced and macrophage proliferation is dominant. Ki67 and macrophage co-staining revealed that S-HDL reduced macrophage proliferation by 67% when normalized to the CD68-positive area (P < 0.01) (Fig. 4, D and E).

To unravel the mechanism by which S-HDL reduced macrophage proliferation, we performed in vitro experiments on a murine macrophage cell line (J774A.1). Cells were incubated with S-HDL at 1.0 or 3.3 μM simvastatin, which effectively inhibited proliferation in a dose-dependent manner (Fig. 4, F and G). At 1.0 μM simvastatin S-HDL, we observed significantly diminished cell proliferation but no change in cell viability, indicating that the antiproliferative effect did not result from diminished cell viability. Finally, the inhibitive effects were largely reverted by the addition of mevalonate, which shows that S-HDL curtails proliferation by blocking the mevalonate pathway.

Designing a two-step treatment regimen
Patients hospitalized after MI or stroke have a high recurrence rate of up to 20% (29). We envision that S-HDL, if translated for human clinical use, could be a short-term infusion therapy in patients with acute coronary syndrome, who benefited from early intervention of high-dose oral statin treatment but to a limited extent (30). Used as an induction therapy, S-HDL would rapidly suppress plaque inflammation during the vulnerable period after an acute coronary syndrome (31). Subsequently, this suppressed inflammation could be sustained by current standard-of-care oral statin therapy. To mimic a clinically relevant scenario, we designed a two-step treatment regimen consisting of a 1-week S-HDL intervention and a subsequent 8-week oral statin treatment. We hypothesize that in Apoe<sup>−/−</sup> mice with advanced atherosclerosis, a 1-week S-HDL treatment rapidly reduces plaque inflammation and, in conjunction with oral statin therapy, results in continuously reduced inflammation.

After developing advanced atherosclerosis, Apoe<sup>−/−</sup> mice were randomly assigned to five groups: (i) a control group (referred to as “Control”) received nine weeks of ongoing HCD; (ii) an oral statin group (“Oral Statin”) received nine weeks of oral statin to mimic the current standard of care; (iii) a two-step treatment regimen group (“Hi + Oral”) received a 1-week high-dose S-HDL followed by eight weeks of oral statin; (iv) an S-HDL only group (“Hi + No”) received a 1-week high-dose of S-HDL followed by eight weeks without treatment; and (v) a high-dose S-HDL plus low-dose S-HDL group (“Positive”), serving as a positive control, received one week of high-dose S-HDL followed by eight weeks of low-dose S-HDL (fig. S6A).
Signal-to-noise ratio (SNR) was calculated by dividing the SNRpost (after Gd-DTPA injection) by the SNRpre (before injection). SNR change = (SNRpost/SNRpre)posttreatment/(SNRpost/SNRpre)pretreatment. One-week S-HDL reduced delayed enhancement of root plaques. Representative T1-weighted MR images of an S-HDL-treated mouse pretreatment and posttreatment were shown in (A). The same mice received fluorescent albumin injections 30 min before being sacrificed. Representative NIRF images showed lower albumin accumulation in S-HDL-treated mice than those that received the placebo. Albumin accumulation in aortic roots, as denoted by dash-line windows in (C), is quantified in (D). Ten Apoe−/− mice were fed iHCD for 20 weeks before receiving 1-week S-HDL intervention (n = 6) or placebo (n = 4). Macrophages in aortic roots were identified with anti-CD68 antibodies (E), and their levels were quantified (F). Macrophages from the aortic roots of Apoe−/− mice fed iHCD for 20 weeks before receiving either 1-week S-HDL (n = 6) or a placebo treatment (n = 6) were isolated with laser capture microdissection. Macrophage inflammatory gene expression was measured by real-time polymerase chain reaction (qPCR). Expression was normalized to housekeeping gene Hprt1. All data are means ± SEM. P values were calculated with Student’s t tests. *P < 0.05, **P < 0.01, ***P < 0.001.

To measure the therapeutic effects, we used immunostaining for the macrophage marker CD68, histology, laser capture microdissection, and real-time PCR (fig. S6B). The immunostaining and histological data were analyzed by a Matlab-derived procedure that provided objective semi-automated measurement (fig. S7). Potential toxic effects on the liver and blood cholesterol levels were assessed by standard blood chemistry procedures.

**Two-step regimen continuously suppresses plaque inflammation**

According to blood chemistry data, the two-step regimen (Hi + Oral) had no toxic effects on the liver and did not change blood cholesterol levels (fig. S8). Histology revealed that one week into the two-step regimen (Hi + Oral), plaque size was significantly reduced by 43% when compared to placebo (P < 0.0001), whereas a 1-week oral statin treatment (Oral Statin) produced no significant changes (fig. S9). Further, the two-step regimen (Hi + Oral) maintained the plaque size reduction throughout the 9-week treatment course when compared to control groups. The two-step regimen (Hi + Oral) also produced a favorable collagen-to-macrophage ratio as early as one week into treatment and maintained that ratio throughout the subsequent 8-week oral statin regimen (fig. S10).

We used anti-CD68 immunostaining to monitor macrophage levels throughout the 9-week treatment course (Fig. 5, A and B) and observed that 1-week S-HDL treatment (Hi-S-HDL) led to 65% fewer macrophages than the control group (P < 0.0001) and 60% fewer than the oral statin group (P < 0.0001) (Fig. 5B). The subsequent 8-week oral statin treatment maintained macrophage reduction and resulted in 33% lower macrophage levels than the control group (P < 0.05). Conversely, the data showed that oral statin treatment alone (Oral Statin) did not yield kick in at five weeks. Significantly lower macrophage levels, as compared to the control group, were achieved only after the full 9-week treatment (40% fewer macrophages than the control group, P < 0.01). At the end of the 9-week treatment, the macrophage levels in the statin-only group were comparable to those in the two-step regimen group (Fig. 5B). Ki67 quantification corroborated that the initial (and very rapid) reduction of plaque inflammation is due to the inhibition of macrophage proliferation (fig. S11). In line with macrophage burden, eight weeks into the course of oral simvastatin treatment, no significant differences in proliferation levels were observed (fig. S11). Therapeutic anti-inflammatory benefits were realized as early as one week into the treatment for the two-step nanomedicine regimen, whereas nine weeks of treatment was required for the statin-only treated mice.

Using laser capture microdissection, we isolated macrophages from aortic roots and measured their expression of key inflammatory genes (Ccl2, Vcam1, Icam1, Cd3, Cxcl12, Cxcl5, Tnfa, Spp1, Il1a, and Il1b) by quantitative PCR (qPCR). As with macrophage levels, we found that 1-week S-HDL treatment significantly reduced the expression of most genes, including Ccl2, Vcam1, Icam1, Cd3, Tnfa, Spp1, Il1a, and Il1b, as compared to controls (Fig. 5C and fig. S12A). A 1-week oral statin treatment did not result in statistically significant reductions in any of the genes (Fig. 5C, left panel, and fig. S12A). In the two-step regimen (Hi + Oral), inflammatory
gene expression could be maintained by the 8-week oral statin treatment (Fig. 5C and fig. S12, B and C). Collectively, these results demonstrate that the two-step regimen not only reduces macrophage accumulation but also renders the remaining cells less inflammatory.

In mice treated with a 1-week S-HDL regimen that was not followed by oral statin therapy (Hi + No), the macrophage levels and inflammatory state were similar to those in the control group at the end of the 9-week treatment period (Fig. 5D and fig. S12C). These data suggest the 8-week oral statin component is essential to continuous suppression of plaque inflammation. In the positive control group, the 8-week oral statin treatment was replaced by an 8-week low-dose S-HDL infusion (Positive). This regimen achieved therapeutic benefits similar to those seen in the two-step (Hi + Oral) and statin-only (Oral Statin) groups (Fig. 5, C and D), albeit at the cost of two intravenous injections per 8 week.

**DISCUSSION**

Here, we show that inhibiting local macrophage proliferation is an effective therapeutic strategy for suppressing atherosclerotic plaque inflammation. More specifically, we use a 1-week nanoparticle therapy (S-HDL) that specifically delivers statins to plaque macrophages, thereby inhibiting their proliferation and reducing inflammation. These therapeutic anti-inflammatory benefits can be maintained by a subsequent 8-week oral statin treatment. The combined 1-week nanotherapy and 8-week oral statin regimen produced no toxic effects on the liver.

Statins, the most widely used cholesterol-lowering drug class, specifically inhibit the mevalonate pathway. This pathway produces isoprenoids, a class of molecules used not only for cholesterol synthesis (32) but also...
for membrane attachment of small GTPases such as Ras and Rho. Rho plays a central role in nuclear factor κB (NF-κB)–mediated inflammatory responses, whereas Ras initiates proliferation of certain cells, including macrophages (33, 34). Systemic statin delivery promotes macrophage emigration from plaques (10), whereas targeted statin delivery to blood monocytes inhibits monocyte recruitment to plaques (35), and both effects are probably related to statins’ inhibitory effects on NF-κB–mediated inflammatory function. For example, in atherosclerotic rabbits, it has been shown that lengthy periods of oral therapy are required to produce therapeutic benefits, which rely on statins’ cholesterol-lowering and systemic anti-inflammatory effects. Our approach positions nanomedicine as a novel therapeutic strategy that capitalizes on statins’ antiproliferative benefits in treating atherosclerosis.

Extensive technical advances in nanotechnology production and formulation chemistry now allow us to incorporate various diagnostic and therapeutic agents in HDL nanoparticles and deliver them to plaque macrophages (21, 38–41). S-HDL’s capacity to inhibit local macrophage proliferation indicates the therapeutic potential of targeted delivery of compounds that are designed to specifically inhibit key processes important in macrophage plaque accumulation. These compounds’ HDL formulations can perhaps reveal the extent to which recruitment, migration, and proliferation can combat inflammation in atherosclerosis.

At the dose used in the current study, conventionally delivered HDL has no therapeutic benefits. In mice, HDL at 400 mg/kg ApoA1 dose has been shown to cause plaque regression (42), and several clinical trials have safely administered HDL at doses up to 80 mg/kg (43, 44). However, the precise therapeutic benefits of HDL remain a topic of ongoing research (45). Our S-HDL nanotherapy was based on the aforementioned clinically validated, reconstituted HDL injectables (44). Because our nanomaterial produces excellent therapeutic benefits at low toxicity, it has significant translational potential for more effectively treating atherosclerosis and its related conditions.

Our nanotherapy treatment strategy may be particularly useful (30) immediately after atherosclerosis-related events, such as MI or stroke, which have an up to 20% recurrence rate within three years (29). Recent studies in both mice (22) and humans (31, 46) suggest that MI itself elevates the inflammatory state of high-risk vulnerable plaques, possibly contributing to recurring events. Additionally, high levels of macrophage proliferation have been found in high-risk human plaques (47–49). In this context, we foresee a scenario in which a hospitalized patient receives intravenous nanoparticle therapy to rapidly reduce plaque inflammation and then subsequent oral statin therapy to maintain the reduced level of plaque inflammation. We demonstrated the potential of a two-step regimen in mice that received a 1-week short-term nanoparticle intervention followed by an 8-week oral statin treatment. This approach reduced plaque inflammation far more quickly than oral statin treatment, which required nine weeks to induce the desired therapeutic effects. The two-step approach, on the other hand, produced comparable therapeutic benefits within one week via S-HDL nanotherapy and maintained them throughout the study period using oral statin therapy. This approach produced similar effects to the positive control protocol of 1-week high-dose S-HDL followed by eight weeks of low-dose S-HDL treatment.
RESEARCH ARTICLE

The latter low-dose nanoparticle treatment was previously shown to effectively prevent plaque formation (21).

This study demonstrates that pharmacologically inhibiting plaque macrophage proliferation by nanotherapy suppresses plaque inflammation and alleviates atherosclerosis. In conjunction with oral statin therapy, rapid and continuous suppression of plaque inflammation could be achieved with minimal toxic effects. This study opens a therapeutic avenue for tackling inflammation in atherosclerosis using a macrophage-targeted antiproliferative strategy.

MATERIALS AND METHODS

Synthesizing S-HDL nanoparticles

Briefly, simvastatin (AK Scientific), 1-myristoyl-2-hydroxy-sn-glycero-phosphocholine (MHPC), and 1,2-dimyristoyl-sn-glycero-3-phosphatidylcholine (DMPC) (Avanti Polar Lipids) were dissolved in chloroform/methanol (4:1 by volume) solvent and dried to form a thin film. Human apolipoprotein A1 (ApoA1) proteins, separated from human plasma, were added to the film, and the solution was incubated at 37°C until the film was hydrated and a homogeneous solution was formed. The solution was sonicated, and aggregates were removed by centrifugation to yield small simvastatin-loaded nanoparticles (S-HDL). For fluorescence detection purposes, either DiR or DiO (Invitrogen) was incorporated when fluorescence imaging techniques were applied. Nanoparticle solution was washed extensively using 100-kD filter (Vivaspin, Vivaprodusts) and filtered through a 0.22-μm nylon filter before being administered to animals. Simvastatin incorporation efficiency was determined by high-performance liquid chromatography (Shimadzu). Preparation of 89Zr-labeled S-HDL is detailed in Supplementary Materials and Methods and used a method previously reported (50).

Animal protocol, diet, and immunostaining

More than 300 Apoe−/− (B6.129P2-Apoetm1Unc) and 5 B6 wild-type (C57BL/6) mice were used for this study. All animal care and procedures were based on an approved institutional protocol from Icahn School of Medicine at Mount Sinai. Five-week-old Apoe−/− male and female mice were purchased from The Jackson Laboratory. In a mechanistic study, the mice were fed an intensely high-cholesterol diet (0.2% weight cholesterol; 15.2% kcal protein, 42.7% kcal carbohydrate, 42.0% kcal fat; Harlan TD.88137) for 16 to 20 weeks (referred to as iHCD). In the therapeutic study, mice were fed a more moderate high-cholesterol diet (0.2% weight cholesterol; 20% kcal protein, 40% kcal carbohydrate, 40% kcal fat; Research Diets Inc.) that needed 26 weeks to induce advanced atherosclerosis in Apoe−/− mice (21) (referred to as HCD). The more moderate diet allowed the mice to reach an average age of 6 to 9 months before receiving treatment to more closely replicate the fact that atherosclerosis mainly affects adult and senior patients (51). Aortic roots were dissected and used for staining with CD68 (clone 1957, Serotec), activated caspase-3 (ab13847, Abcam), or Ki67 (ab15580, Abcam).

Flow cytometry

To evaluate S-HDL’s effects on blood monocytes, 20 Apoe−/− mice received a single intravenous infusion of high-dose S-HDL loaded with a trace amount of DiR. About 40 μl of blood was collected by retro-orbital bleeding before the infusion and at days 0.25, 0.5, 1, 2, 3, 4, 5, and 6 after. Red blood cells in these samples were removed using a red blood cell lysis buffer (BD Biosciences). White blood cells were identified as DAPI−/CD45+. Blood monocytes were identified as DAPI−/CD45+ CD115high SCClow. Monocytes were further identified as Ly-6C−/high subsets on the basis of the expression of Gr-1. Fluorescence intensity of DiR from the cells was used to measure S-HDL uptake levels.

To evaluate the expression levels of adhesion molecules VCAM-1 and ICAM-1, whole aortas were digested using a cocktail of liberase TH (4 U/ml) (Roche), deoxyribonuclease (DNase) I (0.1 mg/ml) (Sigma-Aldrich), and hyaluronidase (60 U/ml) (Sigma-Aldrich) in Dulbecco’s PBS at 37°C for 60 min. ECs were identified as CD45−/CD31−/107cd−high. The expression of ICAM-1 and VCAM-1 on ECs was measured. Antibodies against CD45 (clone 30-F11), CD31 (clone MEC 13.3), CD107α (clone 1D4B), ICAM-1 (clone YN1/1.7.4), VCAM-1 (clone 429), CD115 (AFS98), CR2 (475301), and Ly-6C (AL-21) were used.

To identify aortic macrophages and monocytes, a lineage of antibodies recognizing CD90 (clone 33.2.1), B220 (clone RA3-6B2), CD49b (clone DX5), NK1.1 (clone PK136), Ly-6G (clone 1A8), and Ter-119 (clone T9-119) and antibodies recognizing Ly-6C (clone AL21) were used. Ly-6C−/high monocytes were defined as Lin−/CD11b+ F4/80+ and Ly-6C+ in the blood. All antibodies, purchased from eBioscience, BD Biosciences, and BioLegend, were used at a 1:200 dilution. Aortic macrophages were defined as Lin−/CD11b+ F4/80+ Ly-6C+. Fluorescence was detected by flow cytometry (BD Biosciences LSR II), and the data were analyzed using FlowJo software (Tree Star).

In vivo and in vitro BrdU labeling

BrdU (1 mg) was injected into the peritoneal cavity, and aortas were harvested and digested 24 hours later. Cells from aortas were isolated and stained as described above, and then fixed and permeated according to the manufacturer’s protocol (BD APC-BrdU Kit, 552598). BrdU+ cells were identified by flow cytometry. In vitro labeling was done with J774A.1 cells cultured with Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum. Before being harvested, cells were treated with 1.0 or 3.3 μM S-HDL simvastatin for 24 hours in the presence or absence of 100 μM mevalonate (Sigma-Aldrich) and labeled with BrdU for 45 min before being harvested. Cells were stained and fixed by following the protocol provided by the manufacturer (BD APC-BrdU Kit, 552598), and detected by flow cytometry.

In vivo MRI and ex vivo NIRF

Twenty-two Apoe−/− mice with advanced atherosclerosis were scanned using an electrocardiography (ECG)-gated delayed-enhancement T1-weighted protocol on a 7 T MRI scanner equipped with a 25 mm Quad H1 coil (Bruker). The ECG trigger was derived from two electrodes inserted into the animals’ front limbs. Briefly, the aortic root regions were imaged before and after Gd-DTPA (0.3 mmol/kg, Magnevist, Bayer) injection through the tail vein. A T1-weighted spin echo (repetition time = 800 ms, echo time = 7.543 ms, spatial resolution = 0.117 mm², field of view = 30 mm × 30 mm, slice thickness = 0.5 mm, number of acquisitions = 4, scan time = 15 min) sequence with a black-blood saturation band was used to scan the aortic roots.

Signal enhancement was determined from the SNR of the vessel wall before (SNRpre) and after (SNRpost) Gd-DTPA injection. Seven animals were sacrificed after the first scan and used to determine the baseline (n = 7). The remaining animals received either 1-week S-HDL (n = 8) or placebo (n = 7) and were subjected to a second scan. SNR change was calculated using the following formula: SNR change = (SNRpost/SNRpre)posttreatment − (SNRpost/SNRpre)pretreatment. Thirty minutes before sacrifice, the animals received a Cy5.5-albumin injection (Cy5.5, 1 mg/kg) to measure endothelial permeability of the same region.

Tang et al. Sci. Adv. 2015;1:e1400223 3 April 2015 7 of 9
Aortic roots and arches were collected and imaged by NIRF imaging using the IVIS200 spectrum optical imaging system (PerkinElmer). Total fluorescence signal from aortic roots was quantified using Living Imaging (PerkinElmer).

**Design for therapeutic study and ex vivo analyses**

One hundred twenty-six Apoe<sup>−/−</sup> mice with advanced atherosclerosis were randomly assigned to 14 groups with 9 animals per group. Thirty-six animals received a 1-week placebo treatment (intravenous PBS infusion) and no treatment in the subsequent eight weeks. Atherosclerosis progression was monitored by sacrificing animals at weeks zero (n = 9), 1 (n = 9), and nine (n = 9) during the treatment period (referred to as Control). Twenty-seven animals received oral simvastatin from diet (15 mg/kg per day), and animals were sacrificed for analysis at weeks 1 (n = 9), 5 (n = 9), and 9 (n = 9) (Oral Statin). Twenty-seven animals first received a 1-week high-dose intravenous treatment with S-HDL (simvastatin, 60 mg/kg; ApoA1, 40 mg/kg; four infusions per week) and a subsequent 8-week oral statin treatment (simvastatin, 15 mg/kg per day). Animals were sacrificed at weeks one, five, and nine (Hi + Oral). Eighteen animals received the same 1-week high-dose intravenous infusion of S-HDL but received no treatment in the following eight weeks. Nine animals were sacrificed in weeks five and nine (Hi + No). Eighteen animals received the same 1-week high-dose S-HDL and a subsequent 8-week intravenous infusion of low-dose S-rHDL (simvastatin, 15 mg/kg; ApoA1, 10 mg/kg; two times per week), and nine animals were sacrificed at weeks five and nine (Positive). This treatment schedule is summarized in fig. S6A.

For each animal, 72 aortic root sections (6 μm thick) were prepared. Nine sections per root were stained with hematoxylin and eosin; nine sections, for trichrome stain; nine sections, for anti-CD68 stain (Serotec, clone MCA1957); and three sections, for anti-Ki67 immunofluorescence staining. A custom-made Matlab (MathWorks) procedure was used to quantify the stained areas on the histological sections. Laser capture microdissection was used to extract macrophage mRNA from the remaining sections. These cells’ inflammatory gene expression levels were quantified by real-time PCR. Figure S6B provides an overview. In the therapeutic study, 3522 histology sections were analyzed. The Matlab-based procedures and information for tested genes are described in the Supplementary Materials.

**Statistical analysis**

Results are expressed as means ± SEM. Significance of differences was calculated using Student’s t test and nonparametric Mann–Whitney U test. GraphPad Prism 5.0 for PC (GraphPad Software Inc.) was used for statistical analysis. P < 0.05 was regarded as significant as denoted by “*” if not specifically noted.

**REFERENCES AND NOTES**

1. P. Libby, P. M. Ridker, G. K. Hansson, Progress and challenges in translating the biology of atherosclerosis. *Nature* 473, 317–325 (2011).
2. F. K. Swirski, M. Nahrendorf, Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. *Science* 339, 161–166 (2013).
3. I. Tabas, C. K. Glass, Anti-inflammatory therapy in chronic disease: Challenges and opportunities. *Science* 339, 166–172 (2013).
4. K. J. Moore, F. J. Sheedy, E. A. Fisher, Macrophages in atherosclerosis: A dynamic balance. *Nat. Rev. Immunol.* 13, 709–721 (2013).
5. I. Tabas, Macrophage death and defective inflammation resolution in atherosclerosis. *Nat. Rev. Immunol.* 10, 36–46 (2010).
6. S. Potteaux, E. L. Gautier, S. B. Hutchison, N. van Rooijen, D. J. Rader, M. J. Thomas, M. G. Sorc.
7. T. A. Seimon, Y. Wang, S. Han, T. Senokuchi, D. M. Schrijvers, G. Kuriakose, A. R. Tall, I. A. Tabas.
8. T. Senokuchi, T. Matsumura, M. Sakai, M. Yano, T. Taguchi, T. Matsuo, K. Sonoda, D. Kukidome, K. Imoto, T. Nishikawa, S. Kim-Mitsuyma, Y. Takaku, E. Araki, Statis suppress oxidized low

**SUPPLEMENTARY MATERIALS**

Supplementary material for this article is available at http://advances.sciencemag.org/cgi/content/ full/1/3/e1400223/DC1

Materials and Methods

Fig. S1. S-HDL’s biodistribution in atherosclerotic and wild-type mice.

Fig. S2. Targeting dynamics of S-HDL to blood Ly-6C<sup>hi</sup>/monocytes and their expression of key recruitment proteins.

Fig. S3. Procedure for in vivo DE-MRI.

Fig. S4. Latex bead–based method for tracking macrophage emigration.

Fig. S5. Quantification of apoptosis in aortic roots after S-HDL treatment.

Fig. S6. Designing a two-step treatment regimen.

Fig. S7. Representative binary masks of histological images.

Fig. S8. Blood chemistry results.

Fig. S9. Plaque size changes during the 9-week treatment.

Fig. S10. Changes in macrophage-to-collagen ratio during the 9-week treatment.

Fig. S11. Quantification of proliferating macrophages at weeks 1 and 9 of the treatment.

Fig. S12. Inflammatory gene expression during the 9-week treatment.

Fig. S13. Inflammatory gene expression during the 9-week treatment.

Fig. S14. Inflammatory gene expression during the 9-week treatment.
density lipoprotein–induced macrophage proliferation by inactivation of the small G protein Ras38 MAPK pathway. J. Biol. Chem. 280, 6067–6073 (2005).

21. R. Duivenvoorden, J. Tang, D. P. Cormode, A. J. Mieszawska, D. Izquierdo-Garcia, C. Ozcan, M. J. Otten, N. Zaidi, M. E. Lobatto, S. M. van Rijjs, B. Priem, E. L. Kuan, C. Martel, B. Hewing, H. Sager, M. Nahrendorf, G. Courties, T. Heidt, M. J. Otten, N. Zaidi, M. E. Lobatto, S. M. van Rijs, B. Priem, E. L. Kuan, C. Martel, B. Hewing, M. J. Pittet, L. Hassing, S. van der Staay, S. M. van Rijs, C. Calcagno, M. S. Braza, J. Martin-Moreno, C. Perez-Medina, D. P. Cormode, B. G. Stroes, J. Egashira, Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque inflammation. J. Pathol. 261, 261 (2014).

22. P. K. Shah, J. Yano, O. Reyes, K. Y. Chyu, S. Kaul, C. L.Bigaier, S. Drake, B. Cerezke, High-dose recombinant apolipoprotein A-1 increases mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E–deficient mice. Potential implications for acute plaque stabilization. Circulation 103, 3047–3050 (2001).

23. E. S. Nissen, T. Tsuchida, E. M. Tuzcu, P. Schoenhagen, C. J. Cooper, M. Yasmin, G. M. Eaton, M. A. Lauer, W. S. Sheldon, C. L. Grimes, S. Halpern, T. Crowe, J. C. Blankenship, R. Kerensky, Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 290, 2292–2300 (2003).

24. J. C. Tarde, J. Gregoire, P. L. Lallier, R. Ibraim, J. Lespérance, T. M. Heinonen, S. Kouz, C. Berry, R. Basner, M. A. Lavie, M. C. Guerint, J. Rodes-Cabau; Effect of HDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators, Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: A randomized controlled trial. JAMA 297, 1675–1682 (2007).

25. D. J. Rader, G. K. Hovingh, HDL and cardiovascular disease. Lancet 384, 618–625 (2014).

26. Y. Han, J. Jing, S. Fu, T. Tian, H. Xue, W. Chen, J. Chen, J. H. Reiber, Y. Chen, ST elevation acute myocardial infarction accelerates non-culprit coronary lesion atherosclerosis. Int. J. Cardiovasc. Imaging 30, 253–261 (2014).

27. S. Katsuda, M. D. Coltrera, R. Ross, A. M. Gown, Human atherosclerosis. IV. Immuno-cytchemical analysis of cell activation and proliferation in lesions of young adults. Am. J. Pathol. 142, 1787–1793 (1993).

28. M. D. Reitker, D. Gordon, Active proliferation of different cell types, including lymphocytes, in human atherosclerotic plaques. Am. J. Pathol. 147, 668–677 (1995).

29. E. Lutgens, E. D. de Munick, P. J. Kitaia, J. H. Tordoir, H. J. Wellens, M. J. Daemen, Biphasic pattern of cell turnover characterizes the progression from fatty streaks to ruptured human atherosclerotic plaques. Cardiovasc. Res. 41, 473–479 (1999).

30. C. Pérez-Medina, D. Abdel-Atti, Y. Zhang, V. A. Longo, C. P. Irwin, T. Binderup, J. Ruiz-Cabello, Z. A. Fayad, J. S. Lewis, W. J. M. Mulder, J. Reiber, A. Modular labeling strategy for in vivo PET and near-infrared fluorescence imaging of nanoparticle tumor targeting. J. Nucl. Med. 55, 1706–1711 (2014).

31. J. A. Finegold, P. Asaria, D. F. Francis, Mortality from ischaemic heart disease by country, region, and age: Statistics from World Health Organisation and United Nations. Int. J. Cardiol. 168, 934–945 (2013).

Acknowledgments: We authors thank K. Joyce, for editing the manuscript as well as Kåln School of Medicine at Mount Sinai’s core facilities: flow cytometry core, quantitative PCR core, TIMPs' clinical imaging core, and microscopy core. Funding: This study was funded by the National Heart, Lung, and Blood Institute, NIH Program of Excellence in Nanotechnology (PEN) Award (NHPIN36820100045C, to ZAF); NIH grants R01 HL118440 (W.J.M.M.), R01 HL125703 (W.T.M.), R01 CA155432 (W.J.M.M.), and R01 EB009638 (Z.A.F.); Harold S. Geneen Charitable Trust Award (Z.A.F.); NWO Vidi (W.J.M.M.); NWO Veni (R.D.); Foundation “De Drie Lichten” (M.E.L.); NanoNext; and FP7 NANOOTHERO, AHA Founders Affiliate Predoctoral Award 13PRE14350020-Founders (J.T.). Author contributions: W.J.M.M. supervised the study. W.J.M.M. and J.T., with the help of Z.A.F., E.A.F., F.K.S., M.N., and G.S., designed the experiments. J.T., M.E.L., L.H., S.v.d.S., S.M., and M.E.L., and G.S., performed the experiments. J.T., with the help of C.C., L.H., M.S.B., S.B., F.F., and FP7 NANOATHERO, AHA Founders Affiliate Predoctoral Award 13PRE14350020-Founders (J.T.).